Fierce Biotech: Shasqi snatches $50M Series B
November 11, 2021
Shasqi snatches $50M for chemotherapy-boosting treatments thanks to Arcus, NGM execs
“Shasqi prides itself on being a company of many firsts” writes Emmy Lucas, editorial intern at Fierce, covering healthcare, biotech and pharma.